CO5680108A1 - Compuestos para el tratamiento de la disfuncion sexual femenina - Google Patents
Compuestos para el tratamiento de la disfuncion sexual femeninaInfo
- Publication number
- CO5680108A1 CO5680108A1 CO00084519A CO00084519A CO5680108A1 CO 5680108 A1 CO5680108 A1 CO 5680108A1 CO 00084519 A CO00084519 A CO 00084519A CO 00084519 A CO00084519 A CO 00084519A CO 5680108 A1 CO5680108 A1 CO 5680108A1
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- pde
- compounds
- sexual dysfunction
- female sexual
- Prior art date
Links
- 206010057671 Female sexual dysfunction Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 230000001271 cGMP hydrolyzing effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004392 genitalia Anatomy 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Una composición farmacéutica para uso (o cuando se utiliza) en el tratamiento de la FSD, preferiblemente FSAD, comprendiendo la composición farmacéutica un agente capaz de potenciar el cAMP en los genitales sexuales de una hembra que sufre FSD, preferiblemente FSAD, estando el agente opcionalmente mezclado con un vehículo, diluyente o excipiente farmacéuticamente aceptable; y siendo el citado agente un inhibidor de PDE (I : PDE), siendo la citada PDE una PDE hidrolizante de cAMP (y opcionalmente hidrolizante de cGMP).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9926437A GB9926437D0 (en) | 1999-11-08 | 1999-11-08 | Pharmaceutical |
GB0004021A GB0004021D0 (en) | 2000-02-18 | 2000-02-18 | Pharmaceutical |
GB0013001A GB0013001D0 (en) | 2000-05-26 | 2000-05-26 | Pharmaceutical |
GB0016563A GB0016563D0 (en) | 2000-07-05 | 2000-07-05 | Pharmaceutical |
GB0017141A GB0017141D0 (en) | 2000-07-12 | 2000-07-12 | Pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5680108A1 true CO5680108A1 (es) | 2006-09-29 |
Family
ID=27515922
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00084521A CO5680109A1 (es) | 1999-11-08 | 2000-11-07 | Compuestos para el tratamiento de la disfuncion sexual femenina |
CO00084519A CO5680108A1 (es) | 1999-11-08 | 2000-11-07 | Compuestos para el tratamiento de la disfuncion sexual femenina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00084521A CO5680109A1 (es) | 1999-11-08 | 2000-11-07 | Compuestos para el tratamiento de la disfuncion sexual femenina |
Country Status (25)
Country | Link |
---|---|
US (1) | US6734186B1 (es) |
EP (5) | EP1481667A1 (es) |
JP (9) | JP2001206855A (es) |
KR (7) | KR20010086267A (es) |
CN (5) | CN1636597A (es) |
AT (1) | ATE285249T1 (es) |
AU (6) | AU7140900A (es) |
BR (3) | BR0005266A (es) |
CA (4) | CA2324484A1 (es) |
CO (2) | CO5680109A1 (es) |
CZ (3) | CZ20004110A3 (es) |
DE (1) | DE60016877T2 (es) |
DK (1) | DK1097719T3 (es) |
EA (3) | EA200001042A3 (es) |
ES (1) | ES2233297T3 (es) |
HK (3) | HK1040627A1 (es) |
HU (4) | HUP0004350A2 (es) |
IL (4) | IL139455A0 (es) |
MY (2) | MY141651A (es) |
NO (3) | NO20005618L (es) |
NZ (4) | NZ508006A (es) |
PE (4) | PE20010925A1 (es) |
PL (3) | PL343755A1 (es) |
PT (1) | PT1097719E (es) |
SK (3) | SK16712000A3 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
DK172900B1 (da) | 1998-12-18 | 1999-09-27 | Per Julius Nielsen | Præparat samt kit til brug ved intraoculære operationer |
US20050020547A1 (en) * | 1999-11-08 | 2005-01-27 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
JP2004522720A (ja) * | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
EA006154B1 (ru) | 2001-03-28 | 2005-10-27 | Пфайзер Инк. | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad |
GB0111709D0 (en) * | 2001-05-14 | 2001-07-04 | Pfizer Ltd | Novel pharmaceuticals |
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
JP2006519243A (ja) * | 2003-03-04 | 2006-08-24 | アルタナ ファルマ アクチエンゲゼルシャフト | プリン−6−オン誘導体 |
WO2004094823A2 (en) | 2003-04-23 | 2004-11-04 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
US20060029590A1 (en) * | 2004-06-10 | 2006-02-09 | Christopher Thanos | Administration of neutral endopeptidase to treat inflammatory bowel disease |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
WO2006100557A1 (en) | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
EP2982399B1 (en) | 2006-03-30 | 2017-12-06 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
CA2707218A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
MX2011005932A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
CA2740385A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
EA201170772A1 (ru) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
EP2456440B1 (en) | 2009-07-22 | 2015-08-19 | Merck Sharp & Dohme Corp. | Quinolinone pde2 inhibitors |
US20110152770A1 (en) | 2009-07-30 | 2011-06-23 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
RU2611403C1 (ru) * | 2011-12-05 | 2017-02-21 | Суда Лимитед | Составы в форме спрея для перорального введения и способы введения силденафила |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9381297B2 (en) | 2012-06-07 | 2016-07-05 | Tandem Diabetes Care, Inc. | Sealed infusion device with electrical connector port |
EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
TWI686394B (zh) | 2014-08-07 | 2020-03-01 | 美商內胞醫療公司 | 有機化合物 |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
US10195201B2 (en) | 2015-05-05 | 2019-02-05 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors |
WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
EP3865484B1 (en) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
EP3554489A4 (en) | 2016-12-15 | 2020-06-17 | Evoke Pharma, Inc. | TREATMENT OF MODERATE AND SERIOUS GASTROPARESIS |
US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
CN114533740B (zh) * | 2022-02-10 | 2024-04-12 | 广州威生医药科技有限公司 | 一种公猪气味剂组合物及其应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
US4749717A (en) * | 1987-01-08 | 1988-06-07 | Smithkline Beckman Corporation | Dopamine-beta-hydroxylase inhibitors |
WO1991004042A1 (en) * | 1989-09-18 | 1991-04-04 | Senetek, Plc | Method for inducing vaginal lubrication |
US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US5612314A (en) | 1995-04-21 | 1997-03-18 | Brigham & Women's Hospital | Nitrosylated neuropeptides |
DE19541264A1 (de) * | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
WO1997020821A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
US5798246A (en) | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
GB9608408D0 (en) * | 1996-04-23 | 1996-06-26 | Adams Michael A | Treatment of erectile dysfunction |
ES2186907T3 (es) * | 1996-07-23 | 2003-05-16 | Neurogen Corp | Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1. |
US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
US20020004529A1 (en) * | 1997-10-20 | 2002-01-10 | Gary W. Neal | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US5965718A (en) * | 1997-10-24 | 1999-10-12 | The Scripps Research Institute | Analogs of sarcodictyin and eleutherobin |
GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
JP2001520999A (ja) * | 1997-10-28 | 2001-11-06 | アシビ, エルエルシー | 女性の性的機能不全の処置 |
AUPP010397A0 (en) * | 1997-10-30 | 1997-11-20 | Vaisman, Jakov | Method and composition for treatment of sexual dysfunction |
GB2346877B (en) * | 1997-11-12 | 2001-12-05 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
CN1282249A (zh) * | 1997-12-18 | 2001-01-31 | 内森·厄尔·斯科特 | 用于治疗阳痿和增强性唤起的前列腺素E2/F2α组合剂 |
AU1025899A (en) | 1998-09-16 | 2000-04-03 | Icos Corporation | Carboline derivatives as cgmp phosphodiesterase inhibitors |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20020169101A1 (en) * | 1999-05-10 | 2002-11-14 | Gonzalez Maria Isabel | Treatment of sexual dysfunction |
US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
-
2000
- 2000-11-02 IL IL13945500A patent/IL139455A0/xx unknown
- 2000-11-02 IL IL13945600A patent/IL139456A0/xx unknown
- 2000-11-02 IL IL13945400A patent/IL139454A0/xx unknown
- 2000-11-02 IL IL13945700A patent/IL139457A0/xx unknown
- 2000-11-03 ES ES00309722T patent/ES2233297T3/es not_active Expired - Lifetime
- 2000-11-03 AT AT00309722T patent/ATE285249T1/de not_active IP Right Cessation
- 2000-11-03 SK SK1671-2000A patent/SK16712000A3/sk unknown
- 2000-11-03 EP EP20040020972 patent/EP1481667A1/en not_active Withdrawn
- 2000-11-03 SK SK1672-2000A patent/SK16722000A3/sk unknown
- 2000-11-03 EP EP20000309719 patent/EP1097707A1/en not_active Withdrawn
- 2000-11-03 SK SK1670-2000A patent/SK16702000A3/sk unknown
- 2000-11-03 EP EP00309722A patent/EP1097719B1/en not_active Expired - Lifetime
- 2000-11-03 EP EP00309718A patent/EP1097706A1/en not_active Withdrawn
- 2000-11-03 DK DK00309722T patent/DK1097719T3/da active
- 2000-11-03 EP EP20000309720 patent/EP1097718A1/en not_active Withdrawn
- 2000-11-03 PT PT00309722T patent/PT1097719E/pt unknown
- 2000-11-03 DE DE60016877T patent/DE60016877T2/de not_active Expired - Fee Related
- 2000-11-06 AU AU71409/00A patent/AU7140900A/en not_active Abandoned
- 2000-11-06 AU AU71407/00A patent/AU781400B2/en not_active Ceased
- 2000-11-06 MY MYPI20005202A patent/MY141651A/en unknown
- 2000-11-06 CZ CZ20004110A patent/CZ20004110A3/cs unknown
- 2000-11-06 MY MYPI20005205A patent/MY140534A/en unknown
- 2000-11-06 CZ CZ20004107A patent/CZ20004107A3/cs unknown
- 2000-11-06 CZ CZ20004106A patent/CZ20004106A3/cs unknown
- 2000-11-06 AU AU71411/00A patent/AU781186B2/en not_active Ceased
- 2000-11-06 AU AU71408/00A patent/AU781403B2/en not_active Ceased
- 2000-11-07 NZ NZ508006A patent/NZ508006A/en unknown
- 2000-11-07 CA CA002324484A patent/CA2324484A1/en not_active Abandoned
- 2000-11-07 PE PE2000001188A patent/PE20010925A1/es not_active Application Discontinuation
- 2000-11-07 PE PE2000001187A patent/PE20010926A1/es not_active Application Discontinuation
- 2000-11-07 PE PE2000001185A patent/PE20010817A1/es not_active Application Discontinuation
- 2000-11-07 CN CNA2004100859558A patent/CN1636597A/zh active Pending
- 2000-11-07 HU HU0004350A patent/HUP0004350A2/hu unknown
- 2000-11-07 NZ NZ508012A patent/NZ508012A/en unknown
- 2000-11-07 CA CA002323183A patent/CA2323183A1/en not_active Abandoned
- 2000-11-07 HU HU0004349A patent/HUP0004349A2/hu active IP Right Revival
- 2000-11-07 HU HU0004347A patent/HUP0004347A2/hu not_active Application Discontinuation
- 2000-11-07 CA CA002323464A patent/CA2323464A1/en not_active Abandoned
- 2000-11-07 KR KR1020000065868A patent/KR20010086267A/ko not_active Application Discontinuation
- 2000-11-07 NZ NZ508011A patent/NZ508011A/en unknown
- 2000-11-07 CN CN00137671A patent/CN1322526A/zh active Pending
- 2000-11-07 PE PE2000001186A patent/PE20010924A1/es not_active Application Discontinuation
- 2000-11-07 CN CN00137665A patent/CN1320426A/zh active Pending
- 2000-11-07 NO NO20005618A patent/NO20005618L/no not_active Application Discontinuation
- 2000-11-07 CO CO00084521A patent/CO5680109A1/es unknown
- 2000-11-07 CO CO00084519A patent/CO5680108A1/es unknown
- 2000-11-07 NO NO20005662A patent/NO20005662L/no unknown
- 2000-11-07 KR KR1020000065863A patent/KR20010082545A/ko not_active Application Discontinuation
- 2000-11-07 CN CNA2004100713908A patent/CN1575816A/zh active Pending
- 2000-11-07 KR KR1020000065740A patent/KR20010051481A/ko not_active Application Discontinuation
- 2000-11-07 CN CN00137670A patent/CN1328824A/zh active Pending
- 2000-11-07 HU HU0004348A patent/HUP0004348A2/hu not_active Application Discontinuation
- 2000-11-07 NO NO20005661A patent/NO20005661L/no not_active Application Discontinuation
- 2000-11-07 KR KR1020000065761A patent/KR20010082544A/ko not_active Application Discontinuation
- 2000-11-07 CA CA002323191A patent/CA2323191A1/en not_active Abandoned
- 2000-11-07 BR BR0005266-3A patent/BR0005266A/pt not_active IP Right Cessation
- 2000-11-07 NZ NZ508007A patent/NZ508007A/en unknown
- 2000-11-08 EA EA200001042A patent/EA200001042A3/ru unknown
- 2000-11-08 PL PL00343755A patent/PL343755A1/xx unknown
- 2000-11-08 BR BR0005299-0A patent/BR0005299A/pt not_active IP Right Cessation
- 2000-11-08 US US09/708,392 patent/US6734186B1/en not_active Expired - Fee Related
- 2000-11-08 EA EA200001044A patent/EA006242B1/ru not_active IP Right Cessation
- 2000-11-08 JP JP2000339905A patent/JP2001206855A/ja active Pending
- 2000-11-08 PL PL00343754A patent/PL343754A1/xx unknown
- 2000-11-08 JP JP2000339853A patent/JP2001213802A/ja active Pending
- 2000-11-08 JP JP2000339957A patent/JP2001247479A/ja active Pending
- 2000-11-08 PL PL00343753A patent/PL343753A1/xx unknown
- 2000-11-08 BR BR0005276-0A patent/BR0005276A/pt not_active Application Discontinuation
- 2000-11-08 JP JP2000339949A patent/JP2001247478A/ja active Pending
- 2000-11-08 EA EA200001043A patent/EA006254B1/ru active IP Right Revival
-
2002
- 2002-03-22 HK HK02102197.5A patent/HK1040627A1/zh unknown
- 2002-03-22 HK HK02102195.7A patent/HK1040626A1/zh unknown
- 2002-05-04 HK HK02103406.0A patent/HK1041646A1/zh unknown
-
2004
- 2004-07-01 KR KR1020040050971A patent/KR20040074021A/ko not_active Application Discontinuation
- 2004-07-01 KR KR1020040050973A patent/KR20040074023A/ko not_active Application Discontinuation
- 2004-07-01 KR KR1020040050972A patent/KR20040074022A/ko not_active Application Discontinuation
- 2004-09-15 JP JP2004268608A patent/JP2005013237A/ja active Pending
- 2004-09-15 JP JP2004267669A patent/JP2005021167A/ja not_active Abandoned
- 2004-09-16 JP JP2004269732A patent/JP2005070055A/ja active Pending
- 2004-09-16 JP JP2004269807A patent/JP2005043377A/ja active Pending
-
2005
- 2005-05-18 AU AU2005202166A patent/AU2005202166A1/en not_active Abandoned
- 2005-06-23 AU AU2005202750A patent/AU2005202750A1/en not_active Withdrawn
- 2005-08-11 JP JP2005233224A patent/JP2005350482A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5680108A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
ES2524458T3 (es) | DNasa para el tratamiento de la subfertilidad masculina | |
AR027065A1 (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
PE20040103A1 (es) | Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada | |
UY27465A1 (es) | Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
PE20010053A1 (es) | Formulacion de amoxicilina y clavulanato de potasio | |
ES2421516T3 (es) | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
CL2009001279A1 (es) | Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03). | |
PT1727550E (pt) | Composição farmacêutica que compreende um derivado de benzodiazepina e um inibidor da proteína de fusão do vsr | |
SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
AR047191A1 (es) | Metodos de tratamiento de fibrosis hepatica | |
CR7610A (es) | Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona | |
UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
ES2188995T3 (es) | Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales. | |
PA8515601A1 (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos | |
AR023699A1 (es) | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica | |
AR056517A1 (es) | Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa | |
AR023819A1 (es) | FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION | |
CO5200833A1 (es) | Regimenes de dosificacion para lasofoxifeno | |
UY27031A1 (es) | Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual | |
PA8519501A1 (es) | Farnesil transferasa inhibidora del enantiomero de quinolina 1,2-anillado | |
TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. |